US equities |
TSLA $393.88 ▲+5.82% MU $907.20 ▲+3.38% SPCX $149.21 ▲+1.16% NVDA $215.52 ▲+2.16% META $641.19 ▼-0.22% SNDK $1,262.98 ▲+2.02% AAPL $344.70 ▼-0.87% INTC $90.71 ▲+4.31%
FinancialContent

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

6.500 -0.140 (-2.11%)
Delayed Quote Updated: 11:58 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 26, 2025 ↗
 
Via Benzinga
News headline image
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Assessing Precision BioSciences: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate ↗
Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025. 
Via Benzinga
News headline image
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst ↗
Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV program-driven stock growth. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
From Precision BioSciences, Inc.
Via Business Wire
News headline image
iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
From iECURE, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in Upcoming November Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
From Precision BioSciences
Via Business Wire
News headline image
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report Third Quarter Results on November 4, 2024
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >